BridgeBio Pharma (BBIO) Competitors

BridgeBio Pharma (NASDAQ:BBIO) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability.

Which has preferable valuation and earnings, BBIO or BNTX?

BioNTech has higher revenue and earnings than BridgeBio Pharma. BioNTech is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$221.90M	31.72	-$535.76M	-$2.85	-12.99
BioNTech	$2.75B	8.58	$1.01B	-$3.00	-32.80

Which has more volatility and risk, BBIO or BNTX?

BridgeBio Pharma has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Does the MarketBeat Community believe in BBIO or BNTX?

BridgeBio Pharma received 30 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 71.90% of users gave BridgeBio Pharma an outperform vote while only 46.75% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BridgeBio Pharma	Outperform Votes 174 71.90%	Underperform Votes 68 28.10%
BioNTech	Outperform Votes 144 46.75%	Underperform Votes 164 53.25%

Do analysts rate BBIO or BNTX?

BridgeBio Pharma currently has a consensus target price of $52.90, indicating a potential upside of 42.93%. BioNTech has a consensus target price of $143.73, indicating a potential upside of 46.08%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	0 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.91
BioNTech	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.89

Does the media prefer BBIO or BNTX?

In the previous week, BridgeBio Pharma had 13 more articles in the media than BioNTech. MarketBeat recorded 19 mentions for BridgeBio Pharma and 6 mentions for BioNTech. BridgeBio Pharma's average media sentiment score of 0.93 beat BioNTech's score of 0.89 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	10 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in BBIO or BNTX?

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 24.7% of BridgeBio Pharma shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is BBIO or BNTX more profitable?

BioNTech has a net margin of -15.16% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-241.44%	N/A	-75.69%
BioNTech	-15.16%	-2.35%	-2.05%

Summary

BridgeBio Pharma beats BioNTech on 12 of the 19 factors compared between the two stocks.